{"database":"biostudies-literature","file_versions":[],"scores":null,"additional":{"omics_type":["Unknown"],"submitter":["Doherty J"],"funding":["Abbott Laboratories","University College Dublin,","INITIative Newman Fellowship","Abbott Diagnostics","Diagnostic Division"],"pubmed_abstract":["Evidence suggests patients with inflammatory bowel disease (IBD) receiving TNF-antagonists have attenuated response to vaccination against COVID-19. We sought to determine the impact of IBD and various medications for treatment of IBD on antibody responses to vaccination against COVID-19. Patients with IBD (n=270) and healthy controls (HC, n=116) were recruited prospectively and quantitative antibody responses assessed following COVID-19 vaccination. The impact of IBD and medications for treatment of IBD on vaccine response rates was investigated. 100% of HC seroconverted post-complete vaccination with two vaccine doses. 2% of patients with IBD failed to seroconvert. Median anti-spike protein (SP) immunoglobulin (Ig)G levels post-complete vaccination in our IBD cohort was significantly low"],"journal":["Journal of Crohn's & colitis"],"pagination":["jjac029"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC8903431"],"repository":["biostudies-literature"],"pubmed_title":["Reduced serological response to COVID-19 vaccines in patients with IBD is further diminished by TNF inhibitor therapy; Early results of the VARIATION study (VAriability in Response in IBD Against SARS-COV-2 ImmunisatiON)."],"pmcid":["PMC8903431"],"pubmed_authors":["Sheridan J","Doran P","O Morain N","Mc Dermott E","Stack R","Inzitiari R","Doherty GA","Mulcahy H","Ryan EJ","Daghfal D","Girod P","Cullen G","Doherty J","Horgan G","Tosetto M","O Morain C","Buckley M"],"additional_accession":[]},"is_claimable":false,"name":"Reduced serological response to COVID-19 vaccines in patients with IBD is further diminished by TNF inhibitor therapy; Early results of the VARIATION study (VAriability in Response in IBD Against SARS-COV-2 ImmunisatiON).","description":"Evidence suggests patients with inflammatory bowel disease (IBD) receiving TNF-antagonists have attenuated response to vaccination against COVID-19. We sought to determine the impact of IBD and various medications for treatment of IBD on antibody responses to vaccination against COVID-19. Patients with IBD (n=270) and healthy controls (HC, n=116) were recruited prospectively and quantitative antibody responses assessed following COVID-19 vaccination. The impact of IBD and medications for treatment of IBD on vaccine response rates was investigated. 100% of HC seroconverted post-complete vaccination with two vaccine doses. 2% of patients with IBD failed to seroconvert. Median anti-spike protein (SP) immunoglobulin (Ig)G levels post-complete vaccination in our IBD cohort was significantly low","dates":{"release":"2022-01-01T00:00:00Z","publication":"2022 Feb","modification":"2025-05-29T22:10:46.508Z","creation":"2025-05-29T22:10:46.508Z"},"accession":"S-EPMC8903431","cross_references":{"pubmed":["35176770"],"doi":["10.1093/ecco-jcc/jjac029"]}}